Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 6

1.

Structure-based design of an organoruthenium phosphatidyl-inositol-3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity.

Xie P, Williams DS, Atilla-Gokcumen GE, Milk L, Xiao M, Smalley KS, Herlyn M, Meggers E, Marmorstein R.

ACS Chem Biol. 2008 May 16;3(5):305-16. doi: 10.1021/cb800039y.

2.

Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.

Chen YL, Law PY, Loh HH.

Curr Med Chem Anticancer Agents. 2005 Nov;5(6):575-89. Review.

PMID:
16305480
3.

Targeting phosphoinositide 3-kinase: moving towards therapy.

Marone R, Cmiljanovic V, Giese B, Wymann MP.

Biochim Biophys Acta. 2008 Jan;1784(1):159-85. Epub 2007 Oct 12. Review.

PMID:
17997386
4.

Inhibitors of the PI3K/Akt/mTOR pathway: new hope for breast cancer patients.

Ghayad SE, Cohen PA.

Recent Pat Anticancer Drug Discov. 2010 Jan;5(1):29-57. Review.

PMID:
19751211
5.

PI3K/PTEN signaling in tumorigenesis and angiogenesis.

Jiang BH, Liu LZ.

Biochim Biophys Acta. 2008 Jan;1784(1):150-8. Epub 2007 Sep 29. Review.

PMID:
17964232
6.

Novel inhibitors of the PI3K family.

Carnero A.

Expert Opin Investig Drugs. 2009 Sep;18(9):1265-77. doi: 10.1517/13543780903066798. Review.

PMID:
19589091

Supplemental Content

Support Center